Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Wednesday, August 17, 2016

YIKES! -- CVS CAREMARK - Now Dropping a Few MS Medications from 2017 Prescription Formulary -


                                                                  
  

Click here to receive MS news via e-mail


Do you really think that our Current Healthcare insurance Plans are working?



The CVS Caremark covered insurance plan has dropped AvonexPlegridy and Extavia, three multiple sclerosis disease-modifying therapies, from their 2017 formulary.
You say, OK, but what does that really mean? If your prescription insurance is through CVS Caremark, and you want one of those drugs or one of the other 130 that were announced as off their formulary for next year, you can still get it, but you have to pay the full price.  Your CVS Caremark insurance will no longer cover those costs unless your doctor is able to successfully appeal the formulary decisions.
Why would CVS do this? The bottom line is company profits for the stakeholders. CVS Health’s statement to their stockholders and clients reads:
“CVS Health is taking a stand against egregious drug price increases that unnecessarily add costs for clients and their members. On a quarterly basis, products with egregious cost inflation that have readily-available, clinically-appropriate and more cost-effective alternatives may be evaluated and potentially removed from the formulary. 









MS Views and News
Providing educational information, resources and services for those affected by MS





2 comments:

RCG said...

Email the CEO of CVS Caremark Larry J. Merlo by emailing: larry.merlo@cvscaremark.com
Tell him what you think of him earning over $12million/year while leaving MSer's, HIV patients and cardiac patients high and dry!

RCG said...

Email the CEO of CVS Caremark Larry J. Merlo by emailing: larry.merlo@cvscaremark.com
Tell him what you think of him earning over $12million/year while leaving MSer's, HIV patients and cardiac patients high and dry!